Abstract
Background: Although Chlamydophila pneumoniae (CP)is known to play a role in atherosclerosis and endothelial injury, its past infection on the mortality of coronavirus disease 2019 (COVID-19), which was also reported to be a vascular disease, remains unknown.
Methods: In this retrospective cohort study, we examined 78 COVID-19 patients and 32 bacterial pneumonia patients who visited a tertiary emergency center in Japan between April 1, 2021, and April 30, 2022. CP antibody levels, including IgM, IgG, and IgA, were measured.
Results: Among all patients, the CP IgA-positive rate was significantly associated with age (P = 0.002). Between the COVID-19 and non-COVID-19 groups, no difference in the positive rate for both CP IgG and IgA was observed (P = 1.00 and 0.51, respectively). The mean age and proportion of males were significantly higher in the IgA-positive group than in the IgA-negative group (60.7 vs. 75.5, P = 0.001; 61.5% vs. 85.0%, P = 0.019, respectively). Smoking and dead outcomes were significantly higher both in the IgA-positive group and IgG-positive group (smoking: 26.7% vs. 62.2, P = 0.003; 34.7% vs. 73.1%, P = 0.002, dead outcome: 6.5% vs. 29.8%, P = 0.020; 13.5% vs. 34.6%, P = 0.039, respectively). Although the log-rank test revealed higher 30-day mortality in the IgG-positive group compared to the IgG-negative group (P = 0.032), Cox regression analysis demonstrated no significant difference between the IgG-positive and negative groups (hazard ratio (HR) = 4.10, 95%CI = 0.94-18.0, P = 0.061).
Conclusion: The effect of past CP infection on 30-day mortality in COVID-19 patients was not obvious.
Keywords: antibody, retrospective cohort study, persistent infection, vascular disease, chlamydophila pneumoniae, covid-19
Introduction
Chlamydophila pneumoniae (CP) is known to play a role in atherosclerosis, especially of the coronary artery, by disseminating from the lung to extrapulmonary tissues, such as vascular walls [1,2]. Although CP is thought to be one of the major pathogens causing community-acquired pneumonia in Japan as well as in other countries [3], several studies have shown that its prevalence in Japan has been quite low [4,5]. Severe cardiovascular complications have been reported in patients with coronavirus disease 2019 (COVID-19) [6], and COVID-19 itself is reported to be a vascular disease that causes endothelial injury leading to multiple organ dysfunction [7].
Although CP coinfection rates in COVID-19 patients were reported to be as high as 18% in Italy and 29.1-36.4% in Nigeria [8,9], those in China, Brazil, and India were reported to be 0.3%, 0.0%, and 3.6%, respectively [10-12]. CP coinfection has been reported to aggravate the clinical course of COVID-19 [12].
Lifestyle-related diseases related to atherosclerosis and endothelial injury, such as diabetes mellitus, hypertension, and dyslipidemia, have been reported to worsen the prognosis of COVID-19 [13-15]. Although the prognosis of COVID-19 is not solely due to the advancement of coronary artery disease, it is possible that previous CP infection affects the clinical course of COVID-19 due to its effect of atherosclerosis and endothelial injury to other vessels. However, It is unknown whether past CP infection affects the mortality of COVID-19 owing partly to atherosclerosis and endothelial injury. Therefore, this study aimed to investigate whether previous CP infection affects the mortality of COVID-19.
This article was previously posted on the Research Square preprint server on September 7, 2022.
Materials and methods
Study population
This retrospective cohort study was performed at a tertiary emergency center. COVID-19 patients with COVID pneumonia and non-COVID-19 patients with bacterial pneumonia who were hospitalized at the National Hospital Organization Yokohama Medical Center between April 1, 2021, and April 30, 2022, regardless of severity, and whose CP antibody levels were measured at least once at the time of admission, were included. COVID-19 patients without pneumonia were not included. COVID-19 was diagnosed based on a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction test result. Age, sex, ethnicity, body mass index (BMI), smoking history, vaccination against COVID-19 (VAC), history of HTN, DM, DL, oxygen demand at the time of admission (O2), and clinical outcome were recorded. O2 was categorized into mild (no oxygen administration, oxygen administration using a nasal cannula or a face mask) or severe (oxygen administration using a reservoir mask, a high-flow nasal cannula, or mechanical ventilator). The clinical outcome was categorized as either alive or dead on day 30 after hospitalization.
Serological testing
CP antibodies, including IgM, IgG, and IgA, were measured using an ELNAS Plate CP commercial test kit. CP antibodies were measured at least once, and for some patients, were measured twice at 14-day intervals. The first antibody titers were used for statistical evaluation. Age-related prevalence of CP antibody positivity rates was investigated by dividing age by 10 years. CP antibody positivity was defined as each CP antibody value above the cutoff values. The cutoff values for CP IgM, IgG, and IgA were 1.10, 30, and 8, respectively. Differences in CP antibody positivity rates between the COVID-19 and non-COVID-19 groups were studied. Background data at the time of admission and mortality rate were compared between antibody carriers and non-carriers of both IgG and IgA.
Statistical analysis
We used Spearman’s rank correlation test to determine the relationship between age divided by 10 years and CP antibody (IgG and IgA) positivity rate in both COVID-19 and non-COVID-19 groups. We used Chi-square tests to compare the proportions of categorical variables (such as sex), and t-tests to compare differences in mean age and BMI between groups. Log-rank test and Cox regression analysis were performed to compare the mortality between CP antibody-positive groups and CP antibody-negative groups. The threshold for significance was set at P < 0.05. We used the statistical software EZR version 1.55 for all analyses [16].
Results
Seventy-eight COVID-19 patients with pneumonia and 32 non-COVID-19 patients with bacterial pneumonia were included. None of the 110 patients had positive IgM results. The second measurement of CP antibody levels in 10 COVID-19 patients and two non-COVID-19 patients was performed after a 14-day interval. In only one COVID-19 patient, both CP IgG and IgA levels increased after this interval (See Appendix).
In this study, age was significantly associated with CP IgA-positivity rate (P = 0.002) but not with CP IgG-positivity rate (P = 0.09). None of the patients aged < 47 years had positive CP IgA levels (Figure 1).
Figure 1. Relationship between age and CP antibody positivity rate in all patients studied. P-value was 0.09 for CP IgG, and 0.002 for CP IgA by Spearman’s rank correlation test.
CP, Chlamydophia pneumoniae
Between the COVID-19 and non-COVID-19 groups, no difference in the CP IgG- and IgA-positivity rates was observed (P = 1.00, and 0.51, respectively) (Table 1).
Table 1. Difference of positive rate for CP IgG and IgA between COVID-19 and non-COVID-19 patients.
CP, Chlamydophila pneumoniae; COVID-19, coronavirus disease 2019
| COVID-19 | non-COVID-19 | p.value | |
| IgG positive (%) | 47 (60.3) | 19 (59.4) | 1.00 |
| IgA positive (%) | 25 (33.3) | 13 (40.6) | 0.51 |
The mean age and proportion of males were significantly higher in the IgA-positive group than in the IgA-negative group. Smoking and dead outcomes were significantly higher both in the IgA-positive group and IgG-positive group (Table 2).
Table 2. Background characteristics of CP IgG and IgA positive and negative groups.
BMI, body mass index; VAC, vaccination against COVID-19; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia; O2, oxygen demand at the time of admission; CP, Chlamydophila pneumoniae
| IgG - (n=31) | IgG + (n=47) | p.value | IgA - (n=52) | IgA + (n=26) | p.value | ||
| Age (range) | 62.0 (26-99) | 67.7 (28-94) | 0.18 | 60.7 (26-99) | 75.5 (52-92) | 0.001 | |
| Sex, male | 20 (64.5) | 35 (74.5) | 0.32 | 32 (61.5) | 22 (85.0) | 0.019 | |
| Ethnicity, Asian (%) | 30 (96.8) | 48 (100) | 1.00 | 51 (98.1) | 26 (100) | 1.00 | |
| Ethnicity, Caucasian (%) | 1 (3.2) | 0 (0.0) | 1.00 | 1 (1.9) | 0 (0.0) | 1.00 | |
| BMI (range) | 26.1(17.8-74.8) | 23.7 (13.8-35.4) | 0.18 | 25.7 (17.8-74.8) | 22.5 (13.8-29.9) | 0.089 | |
| Smoking (%) | 8 (26.7) | 28 (62.2) | 0.003 | 17 (34.7) | 19 (73.1) | 0.002 | |
| VAC (%) | 10 (32.2) | 18 (38.3) | 0.77 | 15 (28.8) | 13 (50.0) | 0.21 | |
| HTN (%) | 12 (38.7) | 25 (53.2) | 0.17 | 23 (44.2) | 14 (53.4) | 0.63 | |
| DM (%) | 12 (38.7) | 18 (38.3) | 1.00 | 19 (36.5) | 11 (42.3) | 0.81 | |
| DL (%) | 5 (16.1) | 14 (29.8) | 0.28 | 13 (25.0) | 6 (23.1) | 1.00 | |
| O2, severe (%) | 13 (41.9) | 17 (36.2) | 0.63 | 21 (40.4) | 9 (34.6) | 0.81 | |
| Outcome, dead (%) | 2 (6.5) | 14 (29.8) | 0.020 | 7 (13.5) | 9 (34.6) | 0.039 |
Although the log-rank test revealed higher 30-day mortality only in the IgG-positive group (Figure 2), Cox regression analysis demonstrated no significant difference between the IgG-positive and negative groups.
Figure 2. Log-rank test and Cox regression analysis for CP IgA-positive and IgA-negative groups (A), and CP IgG-positive and IgG-negative groups (B).
CP, Chlamydophila pneumoniae; HR, hazard ratio
Discussion
This study investigated the association between past CP infection and the clinical course of COVID-19 inpatients with pneumonia at a tertiary emergency center. The results showed that the CP IgA-positive rate was significantly associated with age in all patients studied. Although the dead outcome was significantly higher both in the IgA-positive group and IgG-positive group, and the log-rank test revealed higher 30-day mortality in the IgG-positive group compared to the IgG-negative group, Cox regression analysis demonstrated no significant difference between the IgG-positive and negative groups.
Previous studies have shown that the CP coinfection rate in COVID-19 patients was high in several countries other than Japan and aggravated the clinical course of COVID-19. Among our patients studied, no patients were positive for CP IgM, and positive rates of both CP IgG and IgA were not significantly different between the COVID-19 and non-COVID-19 groups (Table 1). This study suggested that acute CP coinfection in COVID-19 patients in Japan was rare and CP coinfection was not especially higher in COVID-19 patients, at least in the area near our hospital. To the best of our knowledge, no other study has investigated the relationship between past CP infections and COVID-19 mortality. The current study suggests that past CP infection may have no effect on the clinical course of COVID-19.
The relationship between age and IgA positivity only supports the findings of past studies that CP IgA positivity suggests chronic CP infection. But our study could not show the higher 30-day mortality rate in the CP IgA-positive group (Figure 2).
It was biologically plausible that the positivity of CP IgA, which may indicate chronic CP infection, was related to a higher mortality rate of COVID-19 patients through arteriosclerosis and endothelial injury, although it was possible that higher mortality in the CP IgA-positive group was confounded by older age, a higher proportion of males, and smoking. A female advantage in COVID-19 has previously been reported by a global meta-analysis on COVID-19 considering both the innate and adaptive immune systems [17]. A previous study in Japan reported that the prevalence of CP IgG in elderly individuals (≥ 60 years) was significantly higher in men than in women (75.5% vs. 64.8%; P = 0.00029) [3]. Although this sex-related difference in antibody positivity was almost consistent with our study, our study indicated that CP IgA was only detectable in patients older than 40 years. CP IgA is considered a marker of immune response and local inflammation in arterial walls induced by CP [18]. Thus, CP IgA, but not CP IgG, was considered a putative marker of chronic infection and subsequent risk of death from not only ischemic heart disease by rupture of atheromatous plaques but also multiple organ dysfunction by endothelial injury. Similarities in the inflammatory processes operating in COVID-19 and atherosclerosis have been suggested [6], and it is possible that arteriosclerosis and endothelial injury due to past CP infection affect the prognosis of COVID-19. The prognosis is worse in older men with COVID-19. In general, older men are immunologically disadvantaged against infection, which may explain the poorer prognosis of older men with COVID-19 and the higher number of CP IgA-positive cases, suggesting persistent CP infection in older men. Although our study did not show direct evidence of persistent infection with CP, persistent infection with CP in older men may worsen the prognosis of COVID-19 via vascular lesions. A relationship between smoking and CP-antibody positivity has been reported [19,20]. Damaged airways and impaired immune response as a result of smoking were considered as the reasons [19]. In CP-antibody-positive patients, smoking was reported to be a risk for coronary artery calcification progression [21]. Our study could not show statistical significance between positive CP serology and mortality. Although multivariate analysis could not be attempted due to the small number of dead cases, older age, male, and smoking history have already been known to be associated with worse prognosis in COVID-19 [22,23], and it is likely that these factors were confounding factors that increased mortality in the CP antibody-positive cases.
This study has several limitations. First, it was a single-center cohort study with a limited number of cases including several variants of SARS-CoV-2. Mortality of COVID-19 cases was highly dependent on its variant types and patient vaccination backgrounds. Second, a comparison of mortality with non-COVID-19 pneumonia could not be performed because none of the non-COVID-19 cases died. Third, biases related to arteriosclerosis due to unobserved subjects can affect the clinical course of COVID-19 patients with past CP infections.
Conclusions
We performed a retrospective cohort study of COVID-19 patients in a tertiary emergency center to investigate the effect of past CP infection on the mortality of the disease. Although it was biologically plausible that CP IgA-positive COVID-19 patients had a poorer prognosis, no statistical difference in 30-day mortality was observed in either CP IgA-positive or CP IgG-positive COVID-19 patients. Further large-scale studies are needed to evaluate the effect of past CP infection on COVID-19 short-time mortality.
Acknowledgments
We would like to thank Editage (www.editage.com) for the English language editing.
Appendices
Table 3. Raw data of patient characteristics.
BMI, body mass index; COVID-19, coronavirus 2019; VAC, vaccination against COVID-19; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia; O2, oxygen demand at the time of admission; IgM2, Chlamydophila pneumoniae IgM two weeks after the initial measurement; IgG2, Chlamydophila pneumoniae IgG two weeks after the initial measurement; IgA2, Chlamydophila pneumoniae IgA two weeks after the initial measurement; NC, nasal cannula; FM, face mask; RM, reservoir mask; HFNC, high flow nasal cannula; y, yes; n, no; M, male; F, female; NA, not available; EIU, enzyme immunoassay units
| Age | Sex | Ethnicity | COVID-19 | BMI (kg/m2) | Smoking | VAC | DM | HTN | DL | O2 | Follow-up period (days) | Outcome | IgM | IgA (EIU) | IgG (EIU) | IgM2 | IgA2 | IgG2 |
| 78 | F | Asian | y | 13.8 | y | n | n | y | n | NC 2l | 8 | alive | 0 | 8 | 147 | NA | NA | NA |
| 89 | M | Asian | y | 15.8 | y | y | n | y | n | FM 9l | 32 | dead | 0 | 43 | 126 | NA | NA | NA |
| 90 | M | Asian | y | 16.0 | y | y | n | y | n | HFNC | 7 | dead | 0 | 12 | 84 | NA | NA | NA |
| 92 | M | Asian | y | 16.2 | n | y | n | y | n | HFNC | 196 | alive | 0 | 53 | 155 | NA | NA | NA |
| 99 | F | Asian | y | 17.8 | n | y | n | y | n | NC 4l | 18 | alive | 0 | 1 | 24 | NA | NA | NA |
| 85 | M | Asian | y | 17.9 | y | NA | y | y | y | none | 13 | alive | 0 | 5 | 40 | NA | NA | NA |
| 81 | F | Asian | y | 18.4 | n | n | n | n | n | Ventilator | 24 | alive | 0 | 0 | 17 | NA | NA | NA |
| 80 | F | Asian | y | 18.6 | n | NA | n | y | n | none | 11 | alive | 0 | 1 | 14 | NA | NA | NA |
| 81 | M | Asian | y | 18.6 | n | n | n | n | n | NC 2l | 194 | alive | NA | 53 | 99 | NA | NA | NA |
| 72 | M | Asian | y | 18.9 | y | n | n | y | y | HFNC | 5 | alive | 0 | 7 | 34 | NA | NA | NA |
| 92 | F | Asian | y | 19.2 | NA | y | n | y | n | none | 214 | alive | 0 | 3 | 52 | NA | NA | NA |
| 83 | M | Asian | y | 19.4 | y | n | y | n | n | NC 4l | 154 | alive | 0 | 12 | 49 | NA | NA | NA |
| 70 | M | Asian | y | 19.8 | y | y | n | n | n | none | 5 | alive | 0 | 3 | 22 | NA | NA | NA |
| 88 | M | Asian | y | 20.0 | n | y | y | n | n | HFNC | 9 | alive | 0 | 21 | 131 | NA | NA | NA |
| 77 | M | Asian | y | 20.2 | y | y | n | y | n | NC 1l | 31 | alive | 0 | 20 | 180 | NA | NA | NA |
| 88 | M | Asian | y | 20.3 | y | y | y | y | n | none | 115 | alive | 0 | 17 | 36 | NA | NA | NA |
| 57 | M | Asian | y | 20.4 | y | n | y | y | y | Ventilator | 194 | alive | 0 | 94 | 191 | 0 | 73 | 165 |
| 71 | M | Asian | y | 20.7 | y | y | y | y | y | Ventilator | 16 | alive | 0 | 6 | 16 | NA | NA | NA |
| 74 | F | Asian | y | 21.0 | n | y | y | y | n | Ventilator | 28 | alive | 0 | 6 | 24 | NA | NA | NA |
| 60 | M | Asian | y | 21.4 | y | y | n | n | y | none | 154 | alive | 0 | 2 | 60 | NA | NA | NA |
| 62 | F | Asian | y | 21.4 | n | n | y | n | n | HFNC | 355 | alive | 0 | 5 | 43 | NA | 5 | 32 |
| 76 | M | Asian | y | 21.4 | y | y | y | y | y | HFNC | 2 | dead | 0 | 5 | 69 | NA | NA | NA |
| 76 | M | Asian | y | 21.7 | NA | y | n | n | n | none | 17 | alive | 0 | 16 | 136 | NA | NA | NA |
| 71 | F | Asian | y | 21.9 | n | y | n | y | y | Ventilator | 15 | alive | 0 | 1 | 15 | NA | NA | NA |
| 59 | M | Asian | y | 22.0 | y | n | y | n | n | Ventilator | 7 | alive | 0 | 0 | 3 | NA | NA | NA |
| 81 | M | Asian | y | 22.0 | n | n | n | y | n | HFNC | 85 | alive | 0 | 7 | 47 | NA | NA | NA |
| 62 | M | Asian | y | 22.1 | y | n | y | n | n | NC 4l | 39 | dead | 0 | 11 | 146 | NA | NA | NA |
| 33 | F | Asian | y | 22.5 | y | n | n | n | n | NC 4l | 25 | alive | 0 | 6 | 94 | NA | NA | NA |
| 63 | F | Asian | y | 22.6 | y | n | n | n | n | NC 4l | 11 | alive | 0 | 3 | 2 | NA | NA | NA |
| 70 | M | Asian | y | 22.6 | y | y | n | n | n | HFNC | 83 | alive | 0 | 15 | 23 | NA | NA | NA |
| 51 | F | Asian | y | 22.8 | n | n | n | n | n | NC 1l | 7 | alive | 0 | 2 | 29 | NA | NA | NA |
| 62 | F | Asian | y | 22.8 | n | n | n | n | n | NC 1l | 12 | alive | 0 | 1 | 11 | NA | NA | NA |
| 72 | F | Asian | y | 22.8 | n | n | n | n | y | NC 1l | 18 | alive | 0 | 6 | 65 | NA | 5 | 53 |
| 90 | M | Asian | y | 22.9 | n | y | y | y | n | HFNC | 427 | dead | 0 | 14 | 44 | NA | NA | NA |
| 68 | M | Asian | y | 23.0 | y | n | n | n | n | Ventilator | 30 | alive | 0 | 0 | 3 | NA | NA | NA |
| 94 | F | Asian | y | 23.3 | n | y | y | y | n | NC 4l | 10 | alive | 0 | 4 | 75 | NA | NA | NA |
| 88 | M | Asian | y | 23.4 | n | n | y | y | y | NC 2l | 38 | alive | 0 | 97 | 69 | NA | NA | NA |
| 53 | M | Asian | y | 23.5 | y | n | n | n | n | NC 1l | 14 | alive | 0 | 1 | 48 | NA | NA | NA |
| 75 | M | Asian | y | 23.5 | n | n | n | n | n | NC 2l | 25 | alive | 0 | 0 | 1 | NA | NA | NA |
| 76 | M | Asian | y | 23.5 | y | NA | n | n | n | NC 3l | 392 | alive | 0 | 17 | 275 | NA | NA | NA |
| 84 | M | Asian | y | 23.9 | n | n | n | y | n | HFNC | 8 | dead | 0 | 3 | 20 | NA | NA | NA |
| 41 | F | Asian | y | 24.1 | n | n | n | n | y | NC 1l | 14 | alive | 0 | 0 | 5 | NA | NA | NA |
| 71 | M | Asian | y | 25.0 | y | n | n | y | n | Ventilator | 17 | dead | 0 | 26 | 185 | NA | NA | NA |
| 81 | F | Asian | y | 25.2 | n | n | y | y | y | Ventilator | 23 | alive | 0 | 2 | 18 | NA | NA | NA |
| 44 | M | Asian | y | 25.3 | y | n | y | n | n | Ventilator | 140 | alive | 0 | 3 | 34 | 0 | 2 | 30 |
| 62 | M | Asian | y | 25.5 | y | n | n | y | y | FM 6l | 30 | dead | 0 | 9 | 135 | 0 | 7 | 82 |
| 65 | M | Asian | y | 25.5 | n | y | n | y | y | HFNC | 43 | alive | 0 | 6 | 44 | NA | NA | NA |
| 56 | M | Asian | y | 25.8 | n | n | y | y | n | Ventilator | 33 | alive | 0 | 5 | 26 | 0 | 8 | 15 |
| 64 | M | Asian | y | 26.0 | n | y | n | y | n | Ventilator | 368 | alive | 0 | 3 | 40 | NA | NA | NA |
| 59 | M | Asian | y | 26.3 | y | n | y | n | n | NC 2l | 8 | alive | 0 | 1 | 34 | NA | 0 | 31 |
| 75 | M | Asian | y | 26.4 | y | n | n | n | n | Ventilator | 319 | dead | 0 | 15 | 43 | NA | NA | NA |
| 65 | F | Asian | y | 26.5 | y | n | y | n | y | Ventilator | 1 | dead | 0 | 8 | 86 | NA | 12 | 130 |
| 34 | F | Asian | y | 26.7 | y | n | n | n | n | NC 1l | 46 | alive | 0 | 4 | 56 | NA | NA | NA |
| 40 | M | Asian | y | 26.7 | n | n | n | y | n | none | 6 | alive | 0 | 2 | 27 | NA | NA | NA |
| 52 | M | Caucasian | y | 26.7 | n | n | n | n | n | NC 1l | 4 | alive | 0 | 0 | 0 | NA | NA | NA |
| 39 | F | Asian | y | 26.8 | y | n | n | n | n | NC 2l | 4 | alive | 0 | 3 | 66 | NA | NA | NA |
| 28 | M | Asian | y | 28.0 | n | y | n | y | n | NC 4l | 11 | alive | 0 | 5 | 73 | NA | NA | NA |
| 38 | F | Asian | y | 28.7 | n | n | y | n | n | HFNC | 9 | alive | 0 | 1 | 0 | NA | NA | NA |
| 57 | M | Asian | y | 28.7 | y | y | n | n | y | NC 3l | 239 | alive | 0 | 18 | 107 | NA | NA | NA |
| 65 | M | Asian | y | 28.7 | y | y | y | n | y | none | 16 | alive | 0 | 8 | 102 | NA | NA | NA |
| 63 | M | Asian | y | 29.0 | n | n | y | n | n | NC 2l | 4 | alive | 0 | 2 | 29 | NA | NA | NA |
| 53 | M | Asian | y | 29.7 | n | n | n | n | n | Ventilator | 13 | dead | NA | 1 | 13 | NA | NA | NA |
| 67 | F | Asian | y | 29.9 | n | n | n | n | n | NC 1l | 29 | alive | NA | 19 | 144 | NA | NA | NA |
| 53 | M | Asian | y | 30.1 | n | n | n | y | y | NC 2l | 397 | alive | NA | 2 | 69 | NA | NA | NA |
| 26 | M | Asian | y | 31.6 | n | y | y | n | n | none | 13 | alive | 0 | 3 | 29 | NA | NA | NA |
| 81 | M | Asian | y | 31.6 | y | n | y | y | n | FM 8l | 16 | dead | NA | 5 | 47 | NA | NA | NA |
| 52 | M | Asian | y | 31.8 | y | n | y | y | n | NC 4l | 30 | alive | NA | 9 | 55 | NA | NA | NA |
| 38 | M | Asian | y | 33.1 | n | n | n | n | n | NC 2l | 83 | alive | 0 | 0 | 13 | NA | NA | NA |
| 49 | F | Asian | y | 33.7 | n | n | y | n | n | Ventilator | 10 | alive | 0 | 4 | 173 | NA | 5 | 85 |
| 34 | M | Asian | y | 35.4 | n | n | n | y | y | HFNC | 104 | dead | 0 | 4 | 82 | 0 | 9 | 50 |
| 47 | M | Asian | y | 35.7 | n | n | y | y | y | none | 12 | alive | 0 | 6 | 23 | NA | NA | NA |
| 26 | M | Asian | y | 74.8 | n | n | y | n | n | NC 3l | 26 | alive | 0 | 1 | 21 | NA | NA | NA |
| 34 | M | Asian | n | NA | NA | NA | n | n | n | Ventilator | NA | alive | NA | 3 | 18 | NA | NA | NA |
| 35 | F | Asian | y | NA | n | n | n | n | n | none | 1 | alive | 0 | 1 | 31 | NA | NA | NA |
| 48 | F | Asian | n | NA | NA | NA | n | n | n | HFNC | NA | alive | 0 | 10 | 83 | NA | 14 | 76 |
| 49 | F | Asian | n | NA | NA | NA | n | n | n | FM 5l | NA | alive | 0 | 4 | 50 | NA | NA | NA |
| 59 | M | Asian | y | NA | NA | n | n | n | n | Ventilator | 25 | alive | NA | 0 | 5 | NA | NA | NA |
| 64 | M | Asian | y | NA | NA | n | y | y | y | Ventilator | NA | alive | NA | 12 | 29 | NA | NA | NA |
| 65 | M | Asian | n | NA | NA | NA | y | y | y | Ventilator | NA | alive | 0 | 12 | 31 | NA | NA | NA |
| 71 | F | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 1 | 12 | 148 | NA | NA | NA |
| 74 | M | Asian | n | NA | NA | NA | NA | NA | NA | FM 7l | NA | alive | 0 | 10 | 248 | NA | NA | NA |
| 74 | M | Asian | n | NA | NA | y | n | y | n | NC 4l | NA | alive | 0 | 11 | 86 | NA | NA | NA |
| 74 | F | Asian | n | NA | NA | NA | NA | NA | NA | none | NA | alive | 0 | 0 | 2 | NA | NA | NA |
| 75 | M | Asian | n | NA | NA | NA | y | n | n | NC 4l | NA | alive | 0 | 7 | 12 | NA | NA | NA |
| 76 | M | Asian | y | NA | NA | y | y | n | n | none | 5 | alive | 0 | 3 | 7 | NA | NA | NA |
| 77 | F | Asian | n | NA | NA | NA | n | n | n | NC 2l | NA | alive | 0 | 12 | 31 | 0 | 10 | 105 |
| 77 | F | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 2 | 26 | NA | NA | NA |
| 77 | M | Asian | n | NA | NA | NA | n | n | n | none | NA | alive | 0 | 5 | 50 | NA | NA | NA |
| 78 | M | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 1 | 24 | NA | NA | NA |
| 79 | M | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | NA | 56 | 256 | NA | NA | NA |
| 79 | M | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 8 | 17 | NA | NA | NA |
| 81 | M | Asian | n | NA | NA | NA | y | y | n | none | NA | alive | 0 | 13 | 104 | NA | NA | NA |
| 82 | F | Asian | n | NA | NA | NA | NA | NA | NA | NC 1l | NA | alive | 0 | 4 | 22 | NA | NA | NA |
| 83 | M | Asian | n | NA | NA | NA | NA | NA | NA | Ventilator | NA | alive | 0 | 22 | 87 | NA | NA | NA |
| 84 | M | Asian | n | NA | NA | NA | NA | NA | NA | NC 1l | NA | alive | 0 | 2 | 8 | NA | NA | NA |
| 84 | M | Asian | n | NA | NA | NA | NA | NA | NA | none | NA | alive | 0 | 9 | 69 | NA | NA | NA |
| 85 | M | Asian | y | NA | NA | y | n | y | n | none | 25 | alive | 0 | 1 | 9 | NA | NA | NA |
| 85 | M | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 3 | 13 | NA | NA | NA |
| 86 | F | Asian | n | NA | NA | NA | NA | NA | NA | NC 1l | NA | alive | 0 | 7 | 10 | NA | NA | NA |
| 86 | F | Asian | n | NA | NA | NA | NA | NA | NA | NC 3l | NA | alive | NA | 33 | 57 | NA | NA | NA |
| 87 | M | Asian | n | NA | NA | NA | n | y | y | NC 2l | NA | alive | 0 | 30 | 74 | NA | NA | NA |
| 87 | F | Asian | n | NA | NA | NA | y | y | y | RM 12l | NA | alive | 0 | 7 | 19 | NA | NA | NA |
| 88 | M | Asian | y | NA | NA | y | n | y | n | none | 25 | alive | 0 | 23 | 76 | NA | NA | NA |
| 88 | F | Asian | n | NA | NA | NA | NA | NA | NA | NC 2l | NA | alive | 0 | 4 | 141 | NA | NA | NA |
| 88 | M | Asian | n | NA | NA | NA | n | y | n | Ventilator | NA | alive | 0 | 7 | 38 | NA | NA | NA |
| 89 | M | Asian | n | NA | NA | NA | n | y | n | NC 3l | NA | alive | 0 | 6 | 70 | NA | NA | NA |
| 89 | F | Asian | n | NA | NA | NA | n | n | n | HFNC | NA | alive | 0 | 5 | 40 | NA | NA | NA |
| 90 | M | Asian | n | NA | NA | NA | NA | NA | NA | NC 1l | NA | alive | 0 | 7 | 32 | NA | NA | NA |
| 90 | F | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 6 | 12 | NA | NA | NA |
| 94 | F | Asian | n | NA | NA | NA | NA | NA | NA | HFNC | NA | alive | 0 | 0 | 8 | NA | NA | NA |
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study. National Hospital Organization Yokohama Medical Center Ethics Committee, Japan issued approval 2022-18
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease. Wang SS, Tondella ML, Bajpai A, et al. Int J Cardiol. 2007;118:215–219. doi: 10.1016/j.ijcard.2006.07.013. [DOI] [PubMed] [Google Scholar]
- 2.Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts. Mannonen L, Markkula E, Puolakkainen M. Med Microbiol Immunol. 2011;200:143–154. doi: 10.1007/s00430-011-0184-3. [DOI] [PubMed] [Google Scholar]
- 3.Seroepidemiology of Chlamydia pneumoniae in Japan between 1991 and 2000. Miyashita N, Fukano H, Yoshida K, Niki Y, Matsushima T. https://jcp.bmj.com/content/55/2/115.long. J Clin Pathol. 2002;55:115–117. doi: 10.1136/jcp.55.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Frequency of detection of Chlamydophila pneumoniae using bronchoalveolar lavage fluid in patients with community-onset pneumonia. Noguchi S, Yatera K, Kawanami T, et al. Respir Investig. 2017;55:357–364. doi: 10.1016/j.resinv.2017.08.003. [DOI] [PubMed] [Google Scholar]
- 5.Where is Chlamydophila pneumoniae pneumonia? Fujita J, Kinjo T. Respir Investig. 2020;58:336–343. doi: 10.1016/j.resinv.2020.06.002. [DOI] [PubMed] [Google Scholar]
- 6.Inflammatory mechanisms in COVID-19 and atherosclerosis: current pharmaceutical perspectives. Sagris M, Theofilis P, Antonopoulos AS, et al. Int J Mol Sci. 2021;22:6607. doi: 10.3390/ijms22126607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.COVID-19 - a vascular disease. Siddiqi HK, Libby P, Ridker PM. Trends Cardiovasc Med. 2021;31:1–5. doi: 10.1016/j.tcm.2020.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. De Francesco MA, Poiesi C, Gargiulo F, et al. J Infect. 2021;82:0–7. doi: 10.1016/j.jinf.2021.01.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria. Davies-Bolorunduro OF, Fowora MA, Amoo OS, et al. Bull Natl Res Cent. 2022;46:115. doi: 10.1186/s42269-022-00811-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Epidemiological study on Mycoplasma pneumoniae and Chlamydia pneumoniae infection of hospitalized children in a single center during the COVID-19 pandemic. Cai F, Shou X, Ye Q. Front Cell Infect Microbiol. 2022;12:843463. doi: 10.3389/fcimb.2022.843463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing. Boschiero MN, Duarte A, Palamim CV, Alvarez AE, Mauch RM, Marson FA. Diagn Microbiol Infect Dis. 2022;102:115576. doi: 10.1016/j.diagmicrobio.2021.115576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Atypical bacterial co-infections among patients with COVID-19: a study from India. Chaudhry R, Sreenath K, Batra P, et al. J Med Virol. 2022;94:303–309. doi: 10.1002/jmv.27324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Wu Z, McGoogan JM. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
- 14.Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Petrilli CM, Jones SA, Yang J, et al. BMJ. 2020;369:0. doi: 10.1136/bmj.m1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Factors associated with COVID-19-related death using OpenSAFELY. Williamson EJ, Walker AJ, Bhaskaran K, et al. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Kanda Y. Bone Marrow Transplant. 2013;48:452–458. doi: 10.1038/bmt.2012.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Peckham H, de Gruijter NM, Raine C, et al. Nat Commun. 2020;11:6317. doi: 10.1038/s41467-020-19741-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. Strachan DP, Carrington D, Mendall MA, et al. BMJ. 1999;318:1035–1039. doi: 10.1136/bmj.318.7190.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Saikku P, Leinonen M, Tenkanen L, et al. Ann Intern Med. 1992;116:273–278. doi: 10.7326/0003-4819-116-4-273. [DOI] [PubMed] [Google Scholar]
- 20.High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents. Paltiel O, Kark JD, Leinonen M, Saikku P. Epidemiol Infect. 1995;114:465–473. doi: 10.1017/s0950268800052171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Chlamydia pneumoniae and progression of subclinical atherosclerosis. Player MS, Mainous AG 3rd, Everett CJ, Diaz VA, Knoll ME, Wright RU. Eur J Prev Cardiol. 2014;21:559–565. doi: 10.1177/2047487312472078. [DOI] [PubMed] [Google Scholar]
- 22.Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. Dessie ZG, Zewotir T. BMC Infect Dis. 2021;21:855. doi: 10.1186/s12879-021-06536-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al. BMJ Open. 2021;11:0. doi: 10.1136/bmjopen-2021-052777. [DOI] [PMC free article] [PubMed] [Google Scholar]